Tags:BioTechDeliveryDrugPlatformProduct
Ataxia Biologics is a clinical-stage biotechnology company that is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. Avaxia’s proprietary oral antibody platform makes direct delivery of antibodies to the GI tract possible by overcoming some of the traditional limitations of antibody therapeutics. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia is developing gut-targeted therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome, and oral mucositis.
Total raised: $24.1M

Investors 3

Funding Rounds 4

DateSeriesAmountInvestorsDeal News
07.06.2013Series B$11.4M-finsmes.co...
18.12.2012Series B$6.4M-vcnewsdail...
14.02.2012Series A$4.1M-vcnewsdail...
10.11.2011Series A$2.2M-finsmes.co...

Mentions in press and media 10

DateTitleDescriptionCategoryAuthorSource
07.06.2013Avaxia Bio...Avaxia Biologics, a Lexington,...funding S...-finsmes.co...
07.06.2013Avaxia Bio... LEXINGTON, MA, Clinical-stag...--vcnewsdail...
18.12.2012Avaxia Bio... LEXINGTON, MA, Clinical-stag...--vcnewsdail...
18.12.2012Avaxia Bio...Avaxia Biologics, Inc., a Lexi...funding U...-finsmes.co...
28.11.2012Avaxia cle...So, rather than being injected...--medcitynew...
14.02.2012Avaxia Bio...Avaxia Biologics, Inc., a Lexi...funding S...-finsmes.co...
14.02.2012Avaxia Bio... LEXINGTON, MA, Privately-hel...--vcnewsdail...
10.11.2011Avaxia Bio...Avaxia Biologics, Inc., a Lexi...funding U...-finsmes.co...
25.03.2008Early Stag...Share Share on Facebook Share ...-Robert Bud...xconomy.co...
-Avaxia cle...A 7-year-old pharmaceutical co...--medcitynew...